Braxia Scientific Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRAX.CN research report →
Companybraxiascientific.com
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders.
- CEO
- Peter Rizakos
- IPO
- 2020
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $1.42M
- P/E
- -0.09
- P/S
- 0.75
- P/B
- 0.71
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.12%
- Op Margin
- -397.00%
- Net Margin
- -697.48%
- ROE
- -248.72%
- ROIC
- -408.30%
Growth & Income
- Revenue
- $1.88M · 26.70%
- Net Income
- $-13,141,704 · -8.30%
- EPS
- $-0.06 · 16.91%
- Op Income
- $-7,480,135
- FCF YoY
- -82.71%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 1.31
- Avg Volume
- 0
Get TickerSpark's AI analysis on BRAX.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BRAX.CN Coverage
We haven't published any research on BRAX.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRAX.CN Report →